Evidence mapPaperPMID 28392139Full record

ArticleVaccine2017

Metformin improves in vivo and in vitro B cell function in individuals with obesity and Type-2 Diabetes.

Alain Diaz, Maria Romero, Thomas Vazquez, Suzanne Lechner, Bonnie B Blomberg, Daniela Frasca

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. The influence of metabolic disorders on adaptive immunity.Cellular & molecular immunology · 2024
    Review
  11. (Multi-) omics studies of ILC2s in inflammation and metabolic diseases.Frontiers in cell and developmental biology · 2024
    Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alain DiazDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Maria RomeroDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Thomas VazquezDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Suzanne LechnerDepartment of Psychiatry, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Bonnie B BlombergDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Daniela FrascaDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA. Electronic address: dfrasca@med.miami.edu.
University of Miami · US

Funding

Regulation of Immunoglobulin Class Switch in Aged MiceR37AG023717 · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2005 to 2005
$303k
NIAID NIH HHS R21 AI096446NIA NIH HHS R01 AG032576NIA NIH HHS R21 AG042826NIA NIH HHS R37 AG023717NIA NIH HHS R56 AG032576
6 · The paper itself

Abstract

Metformin (MET), the first-line medication for Type-2 Diabetes (T2D), has been shown to reduce chronic inflammation indirectly through reduction of hyperglycemia, or directly acting as anti-inflammatory drug. The effects of MET on B lymphocytes is uncharacterized. In the present study, we measured in vivo and in vitro influenza vaccine responses in 2 groups of T2D patients: recently diagnosed but not taking anti-diabetic drugs, and patients taking MET. Results show that B cell function and vaccine responses, hampered by obesity and T2D, are recovered by MET. Moreover, MET used in vitro to stimulate B cells from recently diagnosed T2D patients is also able to reduce B cell-intrinsic inflammation and increase antibody responses, similar to what we have seen in B cells from patients taking MET, who show increased responses to the influenza vaccine in vivo. These results are the first to show an effect of MET on B cells.

Indexed as

Antibodies, ViralB-LymphocytesDiabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsImmunologic FactorsInfluenza, HumanInfluenza VaccinesMaleMetforminMiddle AgedObesityAntibodies, ViralHypoglycemic AgentsImmunologic FactorsInfluenza VaccinesMetforminB cellsInflammationMetformin

Identifiers

PMID28392139
PMCPMC5560851
OpenAlexW2604753146

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.